Our research group at the University of Pittsburgh has recently developed a promising, non-invasive, in vivo PET tracer for imaging amyloid deposition in living humans. Known as Pittsburgh Compound-B (PiB), it has shown much promise in documenting pre-symptomatic amyloid deposition in living subjects destined to develop Alzheimer's disease (AD). PiB also provides a means to determine the natural history of amyloid deposition. While there has been increasing use of PiB to assess amyloid deposition in cognitively normal individuals, the fact remains that despite identifiable risk factors that increase the likelihood of acquiring AD (e.g., age, family history, ApoE4), we cannot identify with certainty those who will develop AD. This makes the study of pre-clinical amyloid deposition difficult in the general population. Conversely, individuals with Down syndrome (DS) are at high risk for developing AD due to the presence of an extra copy of chromosome 21, which codes for the Af3 precursor protein (APP) gene. Postmortem studies have documented the presence of AD pathology in 60 to 90% of adults with DS (with greater pathology increasing with age)(Sylvester, 1984;Wisniewski et aI., 1985). Additionally, symptoms of AD occur in over 40% for DS individuals between 50 and 59 years of age (Hyman, 1992;Schupf et aI., 1998). Thus, the study of adults with DS provides a valuable opportunity to follow the natural history of amyloid deposition and compare it to clinical symptomatology - knowing that approximately half of the group will eventually develop clinical AD and an even greater fraction will develop amyloid deposits. Toward that end, the current multi-center proposal (University of Pittsburgh and Massachusetts General Hospital) will document amyloid deposition in 64 nondemented/ functionally stable adults with DS over a two-year period. We will study three age cohorts: 30-39 yrs, 40-49 yrs and .2:.50 yrs. Subjects will also be assessed for the presence ofthe apolipoprotein-E4 (ApoE4) allele to determine its possible association with accelerated deposition brain amyloid. While we will not complete a natural history study of amyloid deposition in DS during the current project period, this effort will lay the foundation by gathering a valuable cohort of PiB+, non-demented DS subjects that we can follow beyond this grant period with future funding.

Public Health Relevance

The impact of a significant number of adults with Down syndrome developing Alzheimer's disease in their middle and later years is considerable in terms of the burden to family and caretakers, the effect on quality of life for the individual, as well as the costs for providing medical care. Consequently, identification of the nature, cause and outcome of decreased cognitive performance in adult Down syndrome individuals will be an essential component to improving the quality of life of this population.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project (R01)
Project #
Application #
Study Section
Adult Psychopathology and Disorders of Aging Study Section (APDA)
Program Officer
Hsiao, John
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
Schools of Medicine
United States
Zip Code
Handen, Benjamin L; Mazefsky, Carla A; Gabriels, Robin L et al. (2018) Risk Factors for Self-injurious Behavior in an Inpatient Psychiatric Sample of Children with Autism Spectrum Disorder: A Naturalistic Observation Study. J Autism Dev Disord 48:3678-3688
Lao, Patrick J; Handen, Ben L; Betthauser, Tobey J et al. (2018) Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-? Burden in Down Syndrome. J Alzheimers Dis 61:631-644
Lao, Patrick J; Handen, Ben L; Betthauser, Tobey J et al. (2018) Imaging neurodegeneration in Down syndrome: brain templates for amyloid burden and tissue segmentation. Brain Imaging Behav :
Cohen, Ann D; McDade, Eric; Christian, Brad et al. (2018) Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition. Alzheimers Dement 14:743-750
Lao, Patrick J; Handen, Ben L; Betthauser, Tobey J et al. (2017) Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. Alzheimers Dement (Amst) 9:1-9
Hartley, Sigan L; Handen, Benjamin L; Devenny, Darlynne et al. (2017) Cognitive decline and brain amyloid-? accumulation across 3 years in adults with Down syndrome. Neurobiol Aging 58:68-76
Mihaila, Iulia; Hartley, Sigan L; Handen, Benjamin L et al. (2017) Leisure Activity and Caregiver Involvement in Middle-Aged and Older Adults With Down Syndrome. Intellect Dev Disabil 55:97-109
Lao, Patrick J; Betthauser, Tobey J; Hillmer, Ansel T et al. (2016) The effects of normal aging on amyloid-? deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B. Alzheimers Dement 12:380-90
Hartley, Sigan L; Handen, Benjamin L; Devenny, Darlynne A et al. (2014) Cognitive functioning in relation to brain amyloid-? in healthy adults with Down syndrome. Brain 137:2556-63
Handen, Benjamin L; Cohen, Ann D; Channamalappa, Umapathy et al. (2012) Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimers Dement 8:496-501